Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Real-world increase in biomarker testing in lung cancer

ELCC 2022

30 Mar - 2 Apr 2022

Published: 30 Mar 2022

Views: 149

Rating:

Save

Dr Virginia Calvo de Juan - Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain

Dr Virginia Calvo de Juan speaks to ecancer in an online interview for ELCC 2022 about the determination of essential biomarkers in lung cancer based on a real-world data study in Spain.

Dr Calvo details the findings of the study and stresses the importance of these registries being available.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Multiple myeloma in a resource constrained setting

Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda

Multiple myeloma in a resource constrained setting ( Dr Henry Ddungu - Uganda Cancer Institute, Kampala, Uganda )

Updates on lung cancer from WCLC and ESMO 2023

Dr Luis Raez - Memorial Cancer Institute, Miami, USA

Updates on lung cancer from WCLC and ESMO 2023 ( Dr Luis Raez - Memorial Cancer Institute, Miami, USA )

Relapsed Refractory Multiple Myeloma

Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India

$Relapsed Refractory Multiple Myeloma ( Dr Hari Menon - St. Johns National Academy of Health Sciences, Bengaluru, India )$

Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India

Lung Cancer ( Dr Sabita Jiwnani - Tata Memorial Hospital, Mumbai, India )

Genomic testing: Awareness and effective communication between healthcare...

Prof Richard Simcock and Antonella Cardone

Genomic testing: Awareness and effective communication between healthcare professionals and patients ( Prof Richard Simcock and Antonella Cardone )

EGFR mutations in NSCLC - from biomarker to treatment selections in second line

Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo

EGFR mutations in NSCLC - from biomarker to treatment selections in second line ( Prof Nicolas Girard, Prof Keith Kerr, Dr Joshua Reuss and Dr Alfredo Addeo )

Topics under discussion at the WCLC 2022 presidential symposium

Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain

Topics under discussion at the WCLC 2022 presidential symposium ( Dr Enriqueta Felip - Vall d'Hebron University Hospital, Barcelona, Spain )

ASCO 2022: Latest in EGFR positive NSCLC

Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip

ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )

More from ecancer